Learn how to ensure that your health plan – NOT your PBM – benefits from your employees’ generic drug use. This video will explain a) how numerous PBMs are retaining a large portion of the financial benefits resulting from generic drug use; b) how most PBMs manipulate their contracts with clients to do so; and c) what your health plan must do to ensure it obtains 100% of generic drug savings. Save your corporation or union or govt health plan large sums of money by following the basic steps outlined in this video. Our consulting firm has saved our clients millions of dollars in the past year alone using the strategies described. Presenter: Linda Cahn, Esq., President of Pharmacy Benefit Consultants
Video Rating: 0 / 5

Want to Live Extra Years?

Do you use generic drugs? Are they safe? Can they save you money? Tim Colligan, Director of Pharmacy at Optima Health, shares his insights into the value of using generic drugs.

The truth behind Generic Drugs.

Want to Live Extra Years?

Tongue Depressors, 500 Count

• Tongue Depressor
• Medical Care
• Wound Care
• Medical Supplies
• Medical Equipment

Tongue depressors are 6 in x 3/4″ with smooth surfaces and clean edges. (Qty: 500)

Price: $ 6.49

Want to Live Extra Years?

Is it the Right Time to Buy Biotechnology Investments?

July has been a good month for biotech investors. Share prices in the biotech sector as measured by the NYSE Biotechnology Index are up 24% compared to the 6.6% gain for the S&P 500. Earlier in the month, Amgen (AMGN) reported better-than-expected results from a trial of its experimental bone-protecting drug denosumab in patients with advanced breast cancer. Amgen’s shares vaulted 16% on the news.

In the week just ended, the momentum in biotech shares has continued further. While a host of favorable clinical trial results was the bigger driver, a large buyout announcement added the icing to the cake.

Clinical Trial Results

Bringing back memories of the dotcom era, shares of Human Genome Sciences (HGSI) rose nearly 300% to .50 a share after the company reported favorable results for its experimental lupus drug Benlysta. Targacept (TRGT) shares more than doubled to .25 a share after its depression drug candidate met its goals in a mid-stage trial. Onyx Pharmaceutical (ONXX) reported encouraging results for its breast cancer treatment Nexavar to push its shares higher by 21%. Shares of Celgene (CELG) jumped nearly 16% after the company announced significant improvement in progression-free survival of patients taking Revlimid as a first-line treatment for multiple myeloma.

Buyout

Continuing the trend of major pharma-biotech mergers, as in Roche (RHHBY.PK)-Genentech, and Eli Lilly (LLY)-ImClone, Bristol-Myers Squibb (BMY) announced it is buying Medarax (MEDX) for a share. The Medarex takeover implies a net price tag of over billion. Medarax shares jumped nearly 90% on the announcement.

Is it too Late to Board the Biotech Bandwagon?

Given strong gains in biotech shares in recent weeks, it is logical to ask if it is too late to get on the biotech bandwagon. I believe the answer, generally speaking, is no. Notwithstanding uncertainties surrounding health care reform, the fundamentals for biotech companies are reasonably favorable. Yet, one needs to take appropriate care in getting the timing right and in choosing proper investment vehicles.

Fundamentals

Several factors favor the long-term growth of biotech companies. These include an aging population, rising incidence of cancer and other degenerative diseases, and growing recognition that biotech products offer the best solutions for management of these diseases.

Several biotech drugs like Roche’s Avastin and Amgen’s Enbrel have the potential of becoming major blockbuster drugs by 2014. Biotech companies are seeking to expand uses of their approved drugs to treat more diseases. And, unlike drugs made by major pharmaceutical companies, biotech drugs

Want to Live Extra Years?

Question by pzb531: Does anyone know if there is a generic version of the opiate dependance drug “Suboxone”?

Best answer:

Answer by dragfanbob
try methadone

Add your own answer in the comments!

Want to Live Extra Years?

Valuation Of Start-Up Life Science Companies

Valuation of a start-up life science company that offers little more than the promise of success in the future can be very difficult. Stellar results in the basic research laboratory rarely directly result in a cure of disease.  Considering biotech, the drug development process requires many years to determine whether all the effort will translate into monetary returns for a company. Although valuation of the start-up may appear to be more guesswork than proven algorithm, the investment community has a generally accepted approach to valuing biotech companies that are years away from product approval. The generally accepted approach to valuation relies on discounted cash flow (DCF) analysis, which I will explain below.

Valuation of Portfolio
Biotech companies are often valued as a collection of one or more experimental drugs, each drug representing a potential market opportunity. The idea is to treat each promising drug independently within a portfolio. Using DCF analysis of all the promising drugs in the portfolio, one can determine the value of a company.

That is, using DCF one determines the forecasted free cash flow of each drug to establish each drug’s present value. Then the net present value of each drug, along with any cash assets, are added to determine the net value of the company.

Start-up biotech companies often have several drugs in their developmental pipeline. Not all drugs should be included in the valuation. In general, only those drugs in phase I, II, or III are included for valuation. A drug candidate that is in the discovery or non-clinical stage is not a good bet, with less than a 1% chance of reaching the market. Therefore drugs in the non-clinical stage are usually assigned zero value by professional investors.

Sales Revenue Forecasting
The most difficult and most important estimate needed in valuation is that of the sales forecast. Here a determination of expected peak sales is estimated based on the assumption that the drug candidate successfully progresses through clinical trials to FDA approval. The forecast of sales is typically for the first 10 years of the drug’s life.

To forecast sales, start by making assumptions about the drug’s market potential. Use information provided by market research reports to determine the size of the patient group that will use the drug for a given indication. Data are utilized only for those markets were patients will pay market price for the drugs, usually those markets in industrialized countries.

 
To determine a drug’s potential market penetration one must consider many factors. If the candidate is entering a competitive drug market, with limited advantage offered by the candidate drug in terms of

Want to Live Extra Years?